Dexcom (NASDAQ: DXCM) unveils 2030 financial goals and $1.0B share repurchase plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Dexcom, Inc. used its 2026 Investor Day to outline long-term growth and profitability goals and announce a major capital return plan. The company is targeting organic revenue growth of at least 10% every year through 2030, with 2030 non-GAAP gross margin of 67–69%, non-GAAP operating margin of 29–30%, and adjusted EBITDA margin of 36–37%.
Dexcom’s board also authorized a new share repurchase program of up to $1.0 billion of common stock, with repurchases permitted through June 30, 2027. At the same time, the board terminated the prior repurchase program, which had $250.0 million remaining. Repurchases are discretionary and may be made in the open market, privately negotiated transactions, or under Rule 10b5-1 trading plans, in accordance with Rule 10b-18 and other laws.
Positive
- None.
Negative
- None.
Insights
Dexcom sets ambitious 2030 targets and adds a flexible $1B buyback.
Dexcom is signaling confidence by pairing long-range financial targets with a sizable share repurchase authorization. Management aims for organic revenue growth of at least 10% annually through 2030, alongside higher profitability, including 2030 adjusted EBITDA margin of 36–37%.
The new $1.0 billion share repurchase program, running until June 30, 2027, replaces a prior plan that had $250.0 million remaining. Because repurchases are discretionary and subject to market conditions and Rule 10b-18 limits, actual buyback execution and its impact will depend on future decisions and trading windows.
8-K Event Classification
2 items: 7.01, 8.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Organic revenue growth target: 10%+ per year
2030 non-GAAP gross margin: 67–69%
2030 non-GAAP operating margin: 29–30%
+3 more
6 metrics
Organic revenue growth target
10%+ per year
Every year through 2030
2030 non-GAAP gross margin
67–69%
2030 target range
2030 non-GAAP operating margin
29–30%
2030 target range
2030 adjusted EBITDA margin
36–37%
2030 target range
New repurchase authorization
$1.0 billion
Share repurchase program through June 30, 2027
Remaining under prior program
$250.0 million
Amount left when prior program was terminated
Key Terms
Organic Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Profit Margin, Adjusted EBITDA Margin, +2 more
6 terms
Organic Revenue financial
"Organic Revenue growth of 10%+ every year through 2030"
Organic revenue is the sales a company generates from its regular business activities after stripping out extra effects like revenue added or lost from buying or selling other businesses and from currency swings. Think of it as measuring how much a store’s own customers increased spending, not growth from opening new stores or temporary price moves; investors use it to judge the true strength and sustainability of a company’s core demand.
Non-GAAP Gross Profit Margin financial
"2030 Non-GAAP Gross Profit Margin of 67-69%"
Non-GAAP gross profit margin is a company’s gross profit percentage calculated after removing certain expenses or gains that management considers unusual or not part of ongoing operations. Investors use it like looking at a cleaned-up version of a business’s core profitability—similar to judging a car’s fuel efficiency after ignoring one-off trips—because it can highlight underlying trends, but it may vary from standard accounting and can be adjusted in different ways.
Non-GAAP Operating Profit Margin financial
"2030 Non-GAAP Operating Profit Margin of 29-30%"
Adjusted EBITDA Margin financial
"2030 Adjusted EBITDA Margin of 36-37%"
Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.
Rule 10b5-1 regulatory
"trading plans intended to qualify under Rule 10b5-1 under the Exchange Act"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Rule 10b-18 regulatory
"in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 14, 2026
(Exact Name of the Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(858 ) 200-0200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||||||||
Emerging growth company | ||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||||||||
ITEM 7.01. REGULATION FD DISCLOSURE.
On May 14, 2026, DexCom, Inc. (“Dexcom”) held its 2026 Investor Day in Mesa, Arizona, discussing, among other things, information regarding Dexcom’s market opportunities, business strategy, innovation efforts, and long-term financial outlook. Dexcom also posted to its investor relations website an investor presentation used in the 2026 Investor Day event, as well as a replay of the live webcast. The information contained in such website is not part of this Form 8-K.
In addition, Dexcom announced new long-range financial targets at its 2026 Investor Day at the following levels:
•Organic Revenue growth of 10%+ every year through 2030
•2030 Non-GAAP Gross Profit Margin of 67-69%
•2030 Non-GAAP Operating Profit Margin of 29-30%
•2030 Adjusted EBITDA Margin of 36-37%
The information in this Item 7.01 is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof except as shall be expressly set forth by specific reference in such a filing.
Statement Regarding Use of Non-GAAP Financial Measures
This Form 8-K includes non-GAAP financial measures. We have not reconciled our Organic Revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin long range financial targets because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of Organic Revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin is not available without unreasonable effort. The definitions of the non-GAAP financial metrics included herein may be found in Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on February 12, 2026.
ITEM 8.01. OTHER EVENTS.
On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”). In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained available to be repurchased under the program.
Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, at Dexcom’s discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at Dexcom’s discretion.
The Share Repurchase Program does not obligate Dexcom to repurchase any dollar amount or number of shares of Common Stock, and the program may be extended, modified, suspended, or discontinued at any time.
Cautionary Statement Regarding Forward Looking Statements
This Form 8-K contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including Organic Revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin long range financial targets; and potential business plans and opportunities. All forward-looking statements included in this Form 8-K are made as of the date of this Form 8-K, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DEXCOM, INC. | ||||||||
| By: | /s/ JEREME SYLVAIN Jereme Sylvain Executive Vice President, Chief Financial Officer | |||||||
Date: | May 14, 2026 | |||||||
FAQ
What long-term revenue growth target did Dexcom (DXCM) set at its 2026 Investor Day?
Dexcom set a long-term goal for organic revenue to grow at least 10% every year through 2030. This target reflects management’s expectations for sustained expansion of its business over the rest of the decade, based on its current strategy and market opportunities.
What 2030 profitability targets did Dexcom (DXCM) announce for margins?
Dexcom aims for 2030 non-GAAP gross profit margin of 67–69% and non-GAAP operating profit margin of 29–30%. The company also targets a 2030 adjusted EBITDA margin of 36–37%, indicating a focus on improving operating efficiency and cash-generating capability over time.
Are Dexcom’s new financial targets based on GAAP or non-GAAP measures?
Dexcom’s 2030 margin targets use non-GAAP and adjusted metrics: Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin. The company notes it has not reconciled these long-range targets to GAAP because certain impacting items are uncertain or cannot be reasonably predicted.